Jeeejem ......MUCHO HABIA DEMORADO
Amarin down 14% premarket on scrutiny of REDUCE-IT study
Nov. 12, 2018 8:51 AM ET|About:
Amarin Corporation PLC (AMRN)|By:
Douglas W. House, SA News Editor
Amarin (NASDAQ:
AMRN) is off 14% premarket on robust volume in apparent reaction to the details of REDUCE-IT, the large-scale study showing the cardiovascular benefits of Vascepa (icosapent ethyl) in statin-treated patients with triglyceride levels between 135 mg/dL and 499 mg/dL, a much larger potential patient population than its current labeling allows.
SA Contributor DoctoRx has published an
insightful article on the REDUCE-IT data, including suspicions that the placebo group received mineral oil which could affect the absorption of statins. This "anti-statin" effect could raise "bad cholesterol" levels, enhancing the separation of major adverse cardiac events (MACE) between Vascepa and control.
Previously:
Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study (Nov. 11)
https://seekingalpha.com/news/3408458-amarin-14-percent-premarket-scrutiny-reduce-study?app=1#email_link